Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency vs. Outpatient Care for Pediatric Atopic[...]

Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata

Fu J, Goh C. Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata. Br J Dermatol. 2025 Apr 11:ljaf139. doi: 10.1093/bjd/ljaf139. Epub ahead[...]

Measles Resurgence: What Every Dermatologist Should Know

Freeman E, Li C, Castillo D, Ahuja S, Chiu YE, Elewski B, Goh C, Hu J, Rosmarin D, Trinidad J, Rosenbach M. Measles Resurgence: What[...]